Market Research Logo

Global Endometriosis Market: Industry Analysis & Outlook (2018-2025)

Global Endometriosis Market: Industry Analysis & Outlook (2018-2025)

Endometriosis is a chronic condition which leads to severe symptoms if not diagnosed or treated on time. Cells, similar to the line of uterus known as endometrium start growing on the exteriors of uterus like fallopian tube, ovaries, and other internal parts. These tissues continue to act as it does and starts to thicken and breaks down and bleeds with each menstrual cycle and gets trapped, causing painful periods and severe pelvic pain.

The primary symptoms of endometriosis include fatigue, diarrhea, constipation, bloating and severe pain. Endometriosis has multiple treatment options but GnRH agonists have also shown high responder rates and thus believed to be the best in class therapeutics to treat endometriosis because three major drugs are in their final phase of successful clinical trials. These drugs are anticipated to change the complete market scenario with their launch.

The global endometriosis market is expected to experience robust growth post the launch of therapeutic drugs, primarily due to increasing patient base, rise in female population, and increasing healthcare expenditure. However, the market growth is hindered by high R&D expenditures and expensive drug costs.

The report “Global Endometriosis Market: Industry Analysis & Outlook (2018-2025)” analyzes the development of this market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: AbbVie, Myovant Sciences, ObsEva SA, and Neurocrine Biosciences are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global endometriosis market along with the study of the regional markets.


1. Market Overview
1.1 Endometriosis
Table 1: Endometriosis in Uterus
1.2 Symptoms
1.3 Causes
1.4 Treatment & Diagnosis
Table 2: Current Endometriosis Standard of Care
Table 3: Advantages and Drawbacks of Current Endometriosis Standard of Care
Table 4: Potential Drug Candidates
2. Global Endometriosis Therapeutic Market Analysis
2.1 Global Endometriosis Therapeutics Market by Prevalence
Table 5: Global Endometriosis Therapeutics Market by Prevalence (2017)
2.2 Global Endometriosis Therapeutics Market by Severity
Table 6: Global Endometriosis Therapeutics Market by Severity (2017)
2.3 Global Endometriosis Therapeutics Market Forecast by Value
Table 7: Global Endometriosis Therapeutics Market Forecast by Value (2018-2025)
2.4 Global Endometriosis Therapeutics Market Share Forecast by Drugs
Table 8: Global Endometriosis Therapeutics Market Forecast by Drugs (2025)
2.5 Global Endometriosis Therapeutics Market Forecast by Drugs
2.5.1 Global Elagolix Market Forecast by Value
Table 9: Global Elagolix Market Forecast by Value (2018-2025)
2.5.2 Global Relugolix Market Forecast by Value
Table 10: Global Relugolix Market Forecast by Value (2020-2025)
2.5.3 Global OBE2109 Market Forecast by Value
Table 11: Global OBE2109 Market Forecast by Value (2022-2025)
3. Regional Endometriosis Market Analysis
3.1 The US
3.1.1 The US Population with Endometriosis-Forecast
Table 12: The US Population with Endometriosis-Forecast (2017-2025)
3.1.2 The US Population Seeking Treatment for Endometriosis-Forecast
Table 13: The US Population Seeking Treatment for Endometriosis-Forecast (2017-2025)
3.1.3 The US Population Diagnosed/Treated With Endometriosis-Forecast
Table 14: The US Population Diagnosed/Treated With Endometriosis-Forecast (2017-2025)
3.2 Europe
3.2.1 Europe’s Population Seeking Treatment for Endometriosis-Forecast
Table 15: Europe’s Population Seeking Treatment for Endometriosis-Forecast (2017-2025)
3.2.2 Europe’s Population Diagnosed/Treated With Endometriosis-Forecast
Table 16: Europe’s Population Diagnosed/Treated With Endometriosis-Forecast (2017-2025)
3.2.3 Europe’s Population Diagnosed/Treated With Moderate/Severe Endometriosis-Forecast
Table 17: Europe’s Population Diagnosed/Treated With Moderate/Severe Endometriosis-Forecast (2017-2025)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Female Population Worldwide
Table 18: Global Female Population (2013-2017)
4.1.2 Intensifying Expenditure on Public Health Programs for Female
4.1.3 Developing Endometriosis Market in Emerging Economies
4.1.4 Increased Spending on Medicines
Table 19: Global Spending on Medicines (2010-2020E)
Table 20: Total Spending on Medicines in the US (2013-2017)
4.1.5 Increasing Global Healthcare Expenditure
Table 21: Global Healthcare Expenditure (2013-3017)
4.2 Trends and Developments
4.2.1 Launch of Elagolix
4.2.2 Development of New Drugs
Table 22: Major Drugs for Endometriosis in their Development Phases (2017)
4.2.3 Improvement in Minimal and Non-Invasive Diagnostic Methods
4.2.4 Expansion of More Efficient and Advanced Technology
4.3 Issues and Challenges
4.3.1 High R&D Costs
4.3.2 Drug Progress Challenges in Developing Countries
4.3.3 High Cost of Drugs
5. Competitive Landscape
5.1 Revenue and Market Cap
Table 23: Market Cap & Revenue Comparison by Major Players (2017)
5.2 Global Endometriosis Therapeutics Market
5.2.1 Comparison of GnRH Antagonists in Development
Table 24: Comparison of GnRH Antagonists in Development for Endometriosis (2017)
6. Company Profiles
6.1 AbbVie Inc.
6.1.1 Business Overview
Table 25: AbbVie Inc. Revenue Share by Pharmaceutical Products (2017)
6.1.2 Financial Overview
Table 26: AbbVie Inc. Revenue and Net Earnings (2013-2017)
6.1.3 Business Strategies
Table 27: AbbVie Inc. Research and Development Expenditure (2016-2017)
6.2 ObsEva SA
6.2.1 Business Overview
Table 28: ObsEva SA’s Product Pipeline (2017)
6.2.2 Financial Overview
Table 29: ObsEva SA’s Net Income (2014-2017)
6.2.3 Business Strategies
6.3 Neurocrine Biosciences
6.3.1 Business Overview
Table 30: Clinical Pipeline of Neurocrine Biosciences (2017)
6.3.2 Financial Overview
Table 31: Neurocrine Biosciences Revenue (2013-2017)
6.3.3 Business Strategies
6.4 Myovant Sciences Ltd.
6.4.1 Business Overview
Table 32: Myovant Sciences Ltd. Product Pipeline (2017)
6.4.2 Financial Overview
Table 33: Myovant Sciences Ltd.’s Net Loss (2016-2017)
6.4.2 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report